{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-095537","form_type":"8-K","ticker":"DYN","cik":"0001818794","company_name":"Dyne Therapeutics, Inc.","filed_at":"2024-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.650023+00:00","generated_at":"2026-05-31T10:07:41.948846+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Dyne Q2 net loss $65.1M, cash $778.8M; ACHIEVE/DELIVER data positive","bullets":["Q2 2024 net loss $65.1M ($0.70/sh) vs $64.9M ($1.08/sh) in Q2 2023.","Cash, cash equivalents and marketable securities $778.8M, funded at least into H2 2026.","Completed $374.3M public offering (12.075M shares at $31.00) in May 2024.","DYNE-101 in DM1 showed splicing correction and functional improvement; DYNE-251 in DMD showed dystrophin expression exceeding eteplirsen at 6 months.","Company plans to provide registration path update for both programs by year-end 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-095537","json":"https://secwatch.observer/filing/0000950170-24-095537.json","markdown":"https://secwatch.observer/filing/0000950170-24-095537.md","text":"https://secwatch.observer/filing/0000950170-24-095537.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024095537/0000950170-24-095537-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024095537/dyn-20240812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:07:41.948846+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}